Abstract
Since the beginning of this century, target-mediated drug disposition has become a central concept in modeling drug action in drug development. It combines a range of processes, such as turnover, protein binding, internalization, and non-specific elimination, and often serves as a nucleus of more complex pharmacokinetic models. It is simple enough to comprehend but complex enough to be able to describe a wide range of phenomena and data sets. However, the complexity comes at a price: many parameters. In this chapter, we present an overview of the temporal development of the compounds involved after different types of drug doses and offer convenient handles for dissecting data sets in a sophisticated manner in order to estimate the values of these parameters, such as rate constants and pertinent concentrations.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
Here F
L means F approaches L from below and G
L means G approaches L from above.
- 2.
We write f(x) ∼ A ⋅ g(x) as x → 0 (∞) if: f(x)∕g(x) → A as x → 0 (∞).
- 3.
time-Averaged Free Target concentration to Initial target concentration Ratio.
References
Levy G (1994) Pharmacologic target mediated drug disposition. Clin Pharmacol Ther 56:248–252
Sugiyama Y, Hanano M (1989) Receptor-mediated transport of peptide hormones and its importance in the overall hormone disposition in the body. Pharm. Res 6(3):192–202
Mager D, Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Phamacodyn 28(6):507–532
Krzyzanski W, Perez-Ruixo JJ, Vermeulen A (1999) Basic pharmacodynamic models for agents that alter production of natural cells. J. Pharmacokin Biopharm 27:467–489
Mager D, Krzyzanski W (2005) Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res 22(10):1589–1596
Mager, D (2006) Target-mediated drug disposition and dynamics. Biochem Pharmacol 72:1–10
Gibiansky L, Gibiansky E, Kakkar T, Ma P (2008) Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn 35(5):573–591
Krippendorff BF, Kuester K, Kloft C, Huisinga W (2009) Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis. J Pharmacokinet Pharmacodyn 36:239–260
Peletier LA, Gabrielsson J (2009) Dynamics of target-mediated drug disposition. Eur J Pharm Sci 38:445–464
Betts AM, Clark TH, Yang J, Treadway JL, Li M, Giovanelli MA, Abdiche Y, Stone DM, Paralkar VM (2010) The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharm Exper Ther 333:2–13
Peletier LA, Gabrielsson J (2012) Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification, J Pharmacokinet Pharmacodyn 39:429–451
Dua P, Hawkins E, Graaf PH van der (2015) A tutorial on target-mediated drug disposition (TMDD) models. CPT Pharmacometrics Syst Pharmacol 4:324–337. https://doi.org/10.1002/psp4.41
Luu KT, Kraynov E, Kuang B, Vicini P, Zhong W-Z (2013) Modeling, simulation, and translation framework for the preclinical development of monoclonal antibodies. AAPS J 15:551–558
Stein A, Peletier LA (2018) Predicting the onset of nonlinear pharmacokinetics. CPT Pharmacometrics Syst Pharmacol 7:670–677. https://doi.org/10.1002/psp4.12316
Gabrielsson J, Peletier LA, Hjorth S (2018) In vivo potency revisited - Keep the target in sight. Pharmacol Ther 184:177–188
Stein AM, Ramakrishna R (2017) AFIR: a dimensionless potency metric for characterizing the activity of monoclonal antibodies. CPT: Pharmacometrics Syst Pharmacol 6(4):258–266. https://doi.org/10.1002/psp4.12169
Ahmed S, Ellis M, Li H, Pallucchini L, Stein AM (2019) Guiding dose selection of monoclonal antibodies using a new parameter (AFTIR) for characterizing ligand binding systems. J Pharmacokinet Pharmacodyn 46:287–304
Derendorf H, Schmidt S (2020) Rowland and Tozer’s clinical pharmacokinetics and pharmacodynamics: concepts and applications, 5th edn. Wolters Kluwer, Philadelphia
Rosenbaum SE (2011) Basic pharmacokinetics and pharmacodynamics. Wiley, Hoboken
Bauer RJ, Dedrick RL, White ML, Murray MJ, Garovoy MR (1999) Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm 27:397–420
Yan X, Mager DE, Krzyzanski, W (2010) Selection between Michaelis Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn 35:25–47
Ma P (2011) Theoretical considerations of target-mediated drug disposition models: simplifications and approximations. Pharm Res 29:866–882
Marathe A, Krzyzanski W, Mager DE (2009) Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model. J Pharmacokinet Pharmacodyn 36:199–219. https://doi.org/10.1007/s10928-009-9118-8
Lin CC, Segel LA (1988) Mathematics applied to deterministic problems in the natural sciences. In: Classics in applied mathematics, vol 1. Society for Industrial and Applied Mathematics (SIAM), Philadelphia
Michaelis L, Menten, ML (1913) Die Kinetik der Invertinwirkung. Biochem J 49:333–369
Briggs GE, Haldane JBS (1913) A note on the kinetics of enzyme action. Biochem J 49:338–339
Brown AJ (1902) Enzyme action. J Chem Soc 81:373–388
Cornish-Bowden A (2013) The origins of enzyme kinetics. FEBS Lett 587:2725–2730
Gabrielsson J, Peletier LA (2018) Michaelis-Menten from an in vivo perspective: open versus closed systems. AAPS J 20(6):102. https://doi.org/10.1208/s12248-018-0256-z
Wagner JG (1971) A new generalised nonlinear pharmacokinetic model and its implications. In Wagner JG (ed) Biopharmaceutics and relevant pharmacokinetics. Drug Intelligence Publications, Hamilton, p 302–317
Wagner JG (1973) A modern view of pharmacokinetics. J Pharmacokinet Biopharmaceut 1(5):363–401
Aston PJ, Derks G, Raji A, Agoram BM, Graaf PH van der (2011) Mathematical analysis of the pharmacokinetic-pharmacodynamic (PKPD) behaviour of monoclonal antibodies: predicting in vivo potency. J Theor Biol 281:113–121
Peletier LA, Gabrielsson J (2018) New equilibrium models of drug-receptor Interactions derived from target-mediated drug disposition. AAPS J 20:69. https://doi.org/10.1208/s12248-018-0221-x
Gibiansky L, Gibiansky E (2010) Target-mediated drug disposition model for drugs that bind to more than one target. J Pharmacokinet Pharmacodyn 37:323–346. https://doi.org/10.1007/s10928-010-9163-3
Benson N, Graaf PH van der, Peletier LA (2013) Cross-membrane signal transduction of receptor tyrosine kinases (RTKs): from systems biology to systems pharmacology. J Math Biol 66:719–742
Benson N, Graaf PH van der, Peletier LA (2016) Selecting optimal drug-intervention in a pathway involving receptor tyrosine kinases (RTKs). Nonlinear Anal 137:148–170
Gibiansky L, Gibiansky E (2017) Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site. J Pharmacokinet Pharmacodyn 44(5):463–475. https://doi.org/10.1007/s10928-017-9533-1
Koch G, Jusko WJ, Schropp J (2017) Target-mediated drug disposition with drug-drug interaction, Part I: single drug case in alternative formulations. J Pharmacokinet Phamacodyn 44(1):17–26
Koch G, Jusko WJ, Schropp J (2017) Target mediated drug disposition with drug-drug interaction, Part II: competitive and uncompetitive cases. J Pharmacokinet Phamacodyn 44(1):27–42
Cao Y, Jusko WJ (2012) Applications of minimal physiologically-based pharmacokinetic models. J Pharmacokinet Pharmacodyn. 39(6):711–723. https://doi.org/10.1007/s10928-012-9280-2
Shah DK, Betts AM (2012) Towards a platform PBPK model to characterise the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn 39(1):67–86
Li L, Gardner I, Rose R, Jamei M (2014) Incorporating target shedding into a minimal PBPK-TMDD model for monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol3:e96. https://doi.org/10.1038/psp.2013.73
Glassman PM, Balthasar JP (2016) Application of a catenary PBPK model to predict the disposition of “catch and release” anti-PCSK9 antibodies. Int J Pharm 505:69–78
Yuan D, Rode F, Cao Y (2018) A minimal physiologically based pharmacokinetic model with a nested endosome compartment for novel engineered antibodies. AAPS J 20(3):48. https://doi.org/10.1208/s12248-017-0183-4 Refs. [45–47] are not cited in the text. Please provide the citation or delete them from the list.
Cao Y, Jusko WJ (2014) Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn 41:375–387
Gabrielsson J, Peletier LA (2017) Pharmacokinetic steady-states highlight interesting target-mediated disposition properties. AAPS J. 19(3):772–786
Gibiansky L, Gibiansky E (2017) Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site. J Pharmacokinet Phamacodyn 44(5):463–475
Acknowledgement
It is a great pleasure to thank Johan Gabrielsson for many stimulating discussions about this chapter.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Peletier, L.A. (2022). An Extended Model Including Target Turnover, Ligand–Target Complex Kinetics, and Binding Properties to Describe Drug–Receptor Interactions. In: Vanhaelen, Q. (eds) Computational Methods for Estimating the Kinetic Parameters of Biological Systems. Methods in Molecular Biology, vol 2385. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1767-0_2
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1767-0_2
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1766-3
Online ISBN: 978-1-0716-1767-0
eBook Packages: Springer Protocols